Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 434-442

  Yamazaki, Hiroshi ^a   Inoue, Kiyoshi ^a   Shaw, Peter M ^b   Checovich, William J ^b   Guengerich, F Peter ^c   Shimada, Tsutomu ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b INVITROGEN CORPORATION   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUVOXAMINE; KETOCONAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RECOMBINANT ENZYME; SULFAPHENAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ANIMALS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FLUVOXAMINE; HUMANS; HYDROXYLATION; KETOCONAZOLE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; RABBITS; RECOMBINANT PROTEINS; SULFAPHENAZOLE;

EID: 0030864218     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., MEYER, U. A. AND BIRKETT, D. J.: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36: 521-530, 1993.
2. BIRKETT, D. J., ANDERSSON, T. AND MINERS, J. O.: Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Methods Enzymol. 272: 132-139, 1996.
3. BRΦsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E. and Loft, S.: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214, 1993.
4. BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. AND GUENGERICH, F. P.: Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999, 1989.
5. CHANG, M., DAHL, M. -L., TYBRING, G., GOTHARSON, E. AND BERTILSSON, L.: Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5: 358-363, 1995a.
6. CHANG, M., TYBRING, G., DAHL, M. -L., GOTHARSON, E., SAGAR, M., SEENSALU, R. AND BERTILSSON, L.: Interphenotype differences in disposition and effect on gastrin levels of omeprazole -suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol. 39: 511-518, 1995b.
7. CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. AND ISHIZAKI, T.: Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266: 52-59, 1993.
8. CRESPI, C. L., LANGENBACH, R. AND PENMAN, B. W.: The development of a panel of human cell lines expressing specific human cytochrome-P450 cDNAs. In Mutation and the Environment, Part B: Metabolism, Testing Methods, and Chromosomes, ed. by M. L. Mendelsohn and R. J. Albertini, pp. 97-106, Wiley Liss, New York, 1990.
9. CRESPI, C. L.: Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26: 179-235, 1995.
10. DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. AND GOLDSTEIN, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46: 594-598, 1994.
11. GJERVING, K., POULSEN, H. E., DOEHMER, J. AND LOFT, S.: Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol Toxicol 76: 286-288, 1995.
12. GOLDSTEIN, J. A. AND DE MORAIS, S. M. F.: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
13. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM, B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
14. GONZALEZ, F. J.: The molecular biology of cytochrome P450s. Pharmacol. Rev. 40: 243-288, 1989.
15. GONZALEZ, F. J., CRESPI, C. L. AND GELBOIN, H. V.: cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat. Res. 247: 113-127, 1991.
16. GUENGERICH, F. P., WANG, P. AND DAVIDSON, N. K.: Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21: 1698-1706, 1982.
17. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. AND WAXMAN, D. J.: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060, 1986.
18. GUENGERICH, F. P.: Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266: 10019-10022, 1991.
19. GUENGERICH, F. P. AND SHIMADA, T.: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4: 391-407, 1991.
20. GUENGERICH, F. P.: Analysis and characterization of enzymes. In Principles and Methods of Toxicology, ed. 3, ed. by A. W. Hayes, pp. 1259-1313, Raven Press, New York, 1994.
21. IBEANU, G. C., GHANAYEM, B. I., LINKO, P., LI, L., PEDERSEN, L. G. AND GOLDSTEIN, J. A.: Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J. Biol. Chem. 271: 12496-12501, 1996.
22. m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin. Pharmacol. Ther. 59: 647-653, 1996.
23. IMAOKA, S., YAMADA, T., HIROI, T., HAYASHI, K., SAKAI, T., YAHUSAKI, Y. AND FUNAE, Y.: Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem. Pharmacol. 51: 1041-1050, 1996.
24. INOUE, K., YAMAZAKI, H., IMIYA, K., AKASAKA, S., GUENGERICH, F. P. AND SHIMADA, T.: Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113, 1997.
25. ISHIZAKI, T., SOHN, D. -R., KOBAYASHI, K., CHIBA, K., LEE, K. H., SHIN, S. -G., ANDERSSON, T., REGARDH, C. -G., LOU, Y. -C., ZHANG, Y., DAHL, M. -L. AND BERTILSSON, L.: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. 16: 214-217, 1994.
26. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. AND SUGIYAMA, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 1-25, 1997a.
27. IWATSUBO, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A., YOKOI, T., KAMATAKI, T. AND SUGIYAMA, Y.: Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data using human liver microsomes and recombinant P-450 isozymes. J. Pharmacol. Exp. Ther. 282: 909-919, 1997b.
28. JEAN, P., LOPEZ-GARCIA, P., DANSETTE, P., MANSUY, D. AND GOLDSTEIN, J. L.: Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem. 241: 797-804, 1996.
29. JEPPESEN, U., GRAM, L. F., VISTISEN, K., LOFT, S., POULSEN, H. E. AND BRΦsen, K.: Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51: 73-78, 1996a.
30. JEPPESEN, U., LOFT, S., POULSEN, H. E. AND BRΦsen, K.: A fluvoxamine-caffeine interaction study. Pharmacogenetics 6: 213-222, 1996b.
31. KARAM, W. G., GOLDSTEIN, J. A., LASKER, J. M. AND GHANAYEM, B. I.: Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 24: 1081-1087, 1996.
32. KATO, R. AND YAMAZOE, Y.: The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4: 359-362, 1994.
33. KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R. M. AND WATKINS, P. B.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247-259, 1994.
34. LEE, C. A., KADWELL, S. H., KOST, T. A. AND SERBJIT-SINGH, C. J.: CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch. Biochem. Biophys. 319: 157-167, 1995.
35. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
36. MARINAC, J. S., BALIAN, J. D., FOXWORTH, J. W., WILLSIE, S. K., DAUS, J. C., OWEN, R. AND FLOCKHART, D. A.: Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype. Clin. Pharmacol. Ther. 60: 138-144, 1996.
37. MIMURA, M., BABA, T., YAMAZAKI, H., OHMORI, S., INUI, Y., GONZALEZ, F. J., GUENGERICH, F. P. AND SHIMADA, T.: Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab. Dispos. 21: 1048-1056, 1993.
38. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. AND NEBERT, D. W.: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42, 1996.
39. OMURA, T. AND SATO, R.: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
40. PENMAN, B. W., REECE, L., SMITH, T., YANG, C. S., GELBOIN, H. V., GONZALEZ, F. J. AND CRESPI, C. L.: Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3: 28-39, 1993.
41. ROST, K. L. AND ROOTS, L: Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 23: 1491-1497, 1996.
42. RYAN, D. E. AND LEVIN, W.: Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45: 153-239, 1990.
43. SHIMADA, T., SHEA, J. P. AND GUENGERICH, F. P.: A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450. Anal. Biochem. 147: 174-179, 1985.
44. SHIMADA, T., MISONO, K. S. AND GUENGERICH, F. P.: Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J. Biol. Chem. 261: 909-921, 1986.
45. SHIMADA, T., IWASAKI, M., MARTIN, M. V. AND GUENGERICH, F. P.: Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Res. 49: 3218-3228, 1989.
46. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
47. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349, 1996.
48. VANDENBRANDEN, M., RING, B. J., BINKLEY, S. N. AND WRIGHTON, S. A.: Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6: 81-91, 1996.
49. WATKINS, P. B., WRIGHTON, S. A., SCHUETZ, E. G., MOLOWA, D. T. AND GUZELIAN, P. S.: Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80: 1029-1036, 1987.
50. Xu, Z. -H., XIE, H. -G. AND ZHOU, H. -H.: In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br. J. Clin. Pharmacol. 42: 518-521, 1996.
51. YAMAZAKI, H., GUO, Z., PERSMARK, M., MIMURA, M., INOUE, K., GUENGERICH, F. P. AND SHIMADA, T.: Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46: 568-577, 1994a.
52. YAMAZAKI, H., MIMURA, M., SUGAHARA, C. AND SHIMADA, T.: Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α-and coumarin 7-hydroxylations. Biochem. Pharmacol. 48: 1524-1527, 1994b.
53. YAMAZAKI, H., INOUE, K., MIMURA, M., ODA, Y., GUENGERICH, F. P. AND SHIMADA, T.: 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem. Pharmacol. 51: 313-319, 1996a.
54. YAMAZAKI, H., URANO, T., HIROKI, S. AND SHIMADA, T.: Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J. Toxicol. Sci. 21: 215-226, 1996b.